| Literature DB >> 25829809 |
Hyun-Jin Kim1, Kwang-Il Kim2, Young-Seok Cho2, Jeehoon Kang1, Jin Joo Park2, Il-Young Oh2, Chang-Hwan Yoon2, Jung-Won Suh2, Tae-Jin Youn2, In-Ho Chae2, Dong-Ju Choi2.
Abstract
We investigated the effects of weekend admission on adverse cardiac events in patients with non-ST-segment elevation acute coronary syndrome (NSTE-ACS). Patients with NSTE-ACS treated with percutaneous coronary intervention (PCI) were divided into a "weekend group" and a "weekday group" according to the emergency room arrival time. The primary outcome was 30-day major adverse cardiac events (MACE) including cardiac death, recurrent myocardial infarction, repeat revascularization, and urgent PCI. Of 577 patients, 168 patients were allocated to the weekend and 409 patients to the weekday group. The incidence of 30-day MACE was significantly higher in the weekend group (Crude: 15.5% vs. 7.3%, P = 0.005; propensity score matched: 12.8% vs. 4.8%, P = 0.041). After adjustment for all the possible confounding factors, in Cox proportional hazard regression analysis, weekend admission was associated with a 2.1-fold increased hazard for MACE (HR, 2.13; 95% CI, 1.26-3.60, P = 0.005). These findings indicate that weekend admission of patients with NSTE-ACS is associated with an increase in 30-day adverse cardiac event.Entities:
Keywords: Acute Coronary Syndrome; Coronary Artery Disease; Percutaneous Coronary Intervention
Mesh:
Year: 2015 PMID: 25829809 PMCID: PMC4366962 DOI: 10.3346/jkms.2015.30.4.414
Source DB: PubMed Journal: J Korean Med Sci ISSN: 1011-8934 Impact factor: 2.153
Fig. 1Selection of patients. NSTEMI, non-ST-segment elevation myocardial infarction; NSTE-ACS, non-ST-segment elevation acute coronary syndrome; CABG, coronary artery bypass grafting.
Baseline patient characteristics
| Parameters | All (n = 577) | Weekend group (n = 168) | Weekday group (n = 409) | |
|---|---|---|---|---|
| Age (yr) | 63.7 ± 12.8 | 63.3 ± 13.1 | 64.0 ± 12.6 | 0.586 |
| Sex (male) | 412 (71.4%) | 123 (73.2%) | 289 (70.7%) | 0.537 |
| Height (cm) | 163.5 ± 8.8 | 164.3 ± 8.8 | 163.1 ± 8.8 | 0.128 |
| Body weight (kg) | 65.2 ± 11.6 | 66.3 ± 11.3 | 64.7 ± 11.7 | 0.130 |
| Body mass index (kg/m2) | 24.3 ± 3.3 | 24.5 ± 3.1 | 24.2 ± 3.4 | 0.382 |
| Hypertension | 358 (62.0%) | 107 (63.7%) | 251 (61.4%) | 0.602 |
| Diabetes mellitus | 186 (32.2%) | 53 (31.5%) | 133 (32.5%) | 0.821 |
| Hyperlipidemia | 171 (29.6%) | 55 (32.7%) | 116 (28.4%) | 0.296 |
| Smoking, current | 193 (33.4%) | 65 (38.7%) | 128 (31.3%) | 0.087 |
| Previous myocardial infarction | 82 (14.2%) | 24 (14.3%) | 58 (14.2%) | 0.974 |
| Previous CABG | 16 (2.8%) | 6 (3.6%) | 10 (2.4%) | 0.454 |
| Hemoglobin (g/dL) | 13.9 ± 2.1 | 13.9 ± 2.0 | 13.8 ± 2.2 | 0.688 |
| eGFR (mL/min/m2) | 66.0 ± 30.4 | 67.7 ± 32.5 | 65.3 ± 29.5 | 0.382 |
| Total cholesterol (mg/dL) | 190.7 ± 45.6 | 190.1 ± 41.9 | 190.9 ± 47.1 | 0.848 |
| Triglyceride (mg/dL) | 119.8 ± 85.6 | 124.2 ± 91.7 | 118.1 ± 83.0 | 0.440 |
| HDL-cholesterol (mg/dL) | 44.0 ± 10.7 | 43.9 ± 11.5 | 44.0 ± 10.4 | 0.929 |
| LDL-cholesterol (mg/dL) | 99.0 ± 33.8 | 98.4 ± 34.1 | 99.7 ± 33.7 | 0.687 |
| NT-proBNP (pg/mL) | 2,285.6 ± 6,431.9 | 2,117.9 ± 5,678.5 | 2,356.3 ± 6,730.2 | 0.695 |
| hsCRP (mg/dL) | 1.07 ± 2.54 | 1.29 ± 3.13 | 0.99 ± 2.24 | 0.255 |
| CK-MB elevation* | 208 (36.0%) | 73 (43.5%) | 135 (33.0%) | 0.018 |
| Troponin-I elevation* | 350 (60.7%) | 119 (70.8%) | 231 (56.5%) | 0.001 |
| Ischemic ECG change | 0.143 | |||
| ST depression | 169 (29.3%) | 59 (35.1%) | 110 (26.9%) | |
| T-wave inversion | 141 (24.4%) | 38 (22.6%) | 103 (25.2%) | |
| Echocardiographic LV EF (%) | 55.9 ± 11.1 | 55.2 ± 11.0 | 56.2 ± 11.2 | 0.362 |
| TIMI risk score | 0.136 | |||
| Low (0-2) | 231 (40.0%) | 57 (33.9%) | 174 (42.5%) | |
| Intermediate (3-4) | 277 (48.0%) | 87 (51.9) | 190 (46.5%) | |
| High (5-7) | 69 (12.0%) | 24 (14.3%) | 45 (11.0%) | |
| Culprit artery | 0.864 | |||
| Left main coronary artery | 19 (3.3%) | 5 (3.0%) | 14 (3.4%) | |
| Left anterior descending artery | 290 (50.3%) | 84 (49.4%) | 206 (50.6%) | |
| Left circumflex artery | 137 (23.7%) | 43 (25.6%) | 94 (23.0%) | |
| Right coronary artery | 129 (22.4%) | 37 (22.0%) | 92 (22.5%) | |
| CAD extent | 0.726 | |||
| 1 vessel disease | 198 (34.3%) | 60 (35.1%) | 138 (34.0%) | |
| 2 vessel disease | 182 (31.6%) | 49 (29.2%) | 133 (32.5%) | |
| 3 vessel disease | 197 (34.1%) | 60 (35.7%) | 137 (33.5%) | |
| Symptom-to-admission time (hr, median) | 133.2 ± 348.0 (10.0) | 82.7 ± 260.5 (6.0) | 154.0 ± 378.0 (12.0) | 0.010 |
| Admission to-PCI time (hr, median) | 38.1 ± 50.9 (25.0) | 45.3 ± 44.9 (37.6) | 35.2 ± 53.0 (21.7) | 0.030 |
| Concomitant medication | ||||
| Heparin | 531 (92.0%) | 163 (97.0%) | 368 (90.0%) | 0.005 |
| UFH | 471 (81.6%) | 149 (88.7%) | 322 (78.7%) | 0.070 |
| Enoxaparin | 60 (10.4%) | 14 (8.3%) | 46 (11.2%) | 0.070 |
| GpIIb/IIIa R antagonists | 117 (20.3%) | 38 (22.6%) | 79 (19.3%) | 0.370 |
| Tirofiban | 19 (3.3%) | 3 (1.8%) | 16 (3.9%) | 0.303 |
| Abciximab | 100 (17.3%) | 35 (20.8%) | 65 (15.9%) | 0.154 |
| Aspirin | 577 (100.0%) | 168 (100.0%) | 409 (100.0%) | 1.000 |
| Clopidogrel | 577 (100.0%) | 168 (100.0%) | 409 (100.0%) | 1.000 |
| Beta-blocker | 372 (64.5%) | 111 (66.1%) | 261 (63.8%) | 0.633 |
| ACEI | 341 (59.2%) | 107 (63.7%) | 234 (57.4%) | 0.163 |
| ARB | 93 (16.1%) | 27 (16.1%) | 66 (16.1%) | 1.000 |
| DHP CCB | 79 (13.7%) | 24 (14.3%) | 55 (13.4%) | 0.791 |
| Non-DHP CCB | 36 (6.2%) | 12 (7.1%) | 24 (5.9%) | 0.573 |
| Nitrates | 97 (16.8%) | 26 (15.5%) | 71 (17.4%) | 0.626 |
| Statin | 474 (82.3%) | 140 (83.3%) | 334 (81.9%) | 0.720 |
*>1×upper reference limit; CABG, coronary artery bypass grafting; eGFR, estimated glomerular filtration rate; HDL, high-density lipoprotein; LDL, low-density lipoprotein; NT-proBNP, N-terminal-proB-type natriuretic peptide; hsCRP, high-sensitivity C-reactive protein; CK-MB, creatine kinase-myocardial band; ECG, electrocardiography; LV EF, left ventricular ejection fraction; TIMI, thrombolysis in myocardial infarction; CAD, coronary artery disease; PCI, percutaneous coronary intervention; UFH, unfractionated heparin; GpIIb/IIIa R, glycoprotein IIb/IIIa receptor; ACEI, angiotensin-converting-enzyme inhibitor; ARB, angiotensin receptor blocker; DHP CCB, dihydropyridine-calcium channel blocker.
Fig. 2Thirty-day major adverse cardiac events (MACE) for patients with NSTE-ACS who were admitted on weekday or weekend. Of 577 patients, 26 patients in the weekend group (15.5%) and 30 patients in the weekday group (7.3%) had MACE within 30 days. The difference between the two groups was statistically significant (P = 0.005).
Thirty-day clinical outcomes
| Outcomes | All (n = 577) | Weekend group (n = 168) | Weekday group (n = 409) | |
|---|---|---|---|---|
| MACE* | 56 (9.7%) | 26 (15.5%) | 30 (7.3%) | 0.005 |
| Cardiac death | 7 (1.2%) | 5 (3.0%) | 2 (0.5%) | 0.025 |
| Recurrent MI | 2 (0.3%) | 2 (1.2%) | 0 (0.0%) | 0.084 |
| Repeat revascularization | 4 (0.7%) | 2 (1.2%) | 2 (0.5%) | 0.584 |
| Urgent PCI | 49 (8.5%) | 21 (12.5%) | 28 (6.8%) | 0.033 |
| CK-MB elevation, overall | 320 (55.5%) | 117 (69.6%) | 203 (49.6%) | < 0.001 |
| Peak CK-MB level | 62.2 ± 142.3 | 74.0 ± 108.6 | 57.4 ± 153.9 | 0.080 |
| Troponin-I elevation, overall | 454 (78.7%) | 149 (88.7%) | 305 (74.6%) | < 0.001 |
| Peak Troponin-I level | 22.5 ± 67.8 | 30.3 ± 78.8 | 19.4 ± 62.6 | 0.203 |
*MACE (major adverse cardiac event) including cardiac death, recurrent MI, repeat revascularization, and unplanned urgent PCI. MI, myocardial infarction; PCI, percutaneous coronary intervention; CK-MB, creatine kinase-myocardial band.
Distribution of the occurrence of MACE
| MACE duration | All | Weekend group (n = 26) | Weekday group (n = 30) | |
|---|---|---|---|---|
| Day 1-5 | 52 (92.9%) | 23 (88.4%) | 29 (96.7%) | 0.490 |
| Day 6-10 | 2 (3.6%) | 1 (3.8%) | 1 (3.3%) | - |
| Day 11-20 | 1 (1.8%) | 1 (3.8%) | 0 (0%) | - |
| Day 21-30 | 1 (1.8%) | 1 (3.8%) | 0 (0%) | - |
Fig. 3Outcomes and baseline characteristics according to ER admission day. (A) Thirty-day major adverse cardiac events (MACE) according to ER admission day. The incidence of MACE shows a trend of increase from Monday to Sunday. (B) Baseline Troponin-I elevation according to ER admission day. Distribution of patients with elevated baseline troponin-I shows a trend of gradual increase from Monday to Sunday. (C) Baseline electrocardiographic ST-segment depression according to ER admission day. Distribution of patients with baseline ECG change does not show statistically significant trend. (D) Baseline high TIMI risk score according to ER admission day. Distribution of patients with high TIMI risk score did not get statistically significant trend. (E) Admission to-PCI time according to ER admission day. The admission-to-PCI time has a trend of gradual increase from Monday to Saturday, revealing significantly longer time on Saturday than Tuesday or Sunday. (F) Symptom to-admission time according to ER admission day. The distribution of symptom-to-admission time shows a trend of longest time on Monday and gradual decrease toward the weekend, without statistical significance.
Eighteen-month cumulative clinical outcomes
| Outcomes | All (n = 577) | Weekend group (n = 168) | Weekday group (n = 409) | |
|---|---|---|---|---|
| MACE* | 111 (19.2%) | 32 (19.0%) | 79 (19.3%) | 0.941 |
| Cardiac death | 12 (2.1%) | 6 (3.7%) | 6 (1.5%) | 0.110 |
| MI | 8 (1.4%) | 3 (1.8%) | 5 (1.3%) | 0.605 |
| Repeat revascularization | 69 (12.3%) | 8 (4.9%) | 61 (15.4%) | 0.001 |
| Urgent PCI | 49 (8.5%) | 21 (12.5%) | 28 (6.8%) | 0.033 |
*MACE (major adverse cardiac event) including cumulative cardiac death, MI, repeat revascularization, and unplanned urgent PCI. MI, myocardial infarction; PCI, percutaneous coronary intervention.
Baseline characteristics in propensity-score matched population
| Parameters | All (n = 250) | Weekend group (n = 125) | Weekday group (n = 125) | |
|---|---|---|---|---|
| Age (yr) | 62.9 ± 13.4 | 62.64 ± 13.7 | 63.14 ± 13.12 | 0.761 |
| Sex (male) | 183 (73.2%) | 91 (72.8%) | 92 (73.6%) | 1.000 |
| Height (cm) | 164.6 ± 8.9 | 164.5 ± 9.0 | 164.7 ± 8.8 | 0.828 |
| Body weight (kg) | 67.0 ± 11.9 | 66.8 ± 11.8 | 67.2 ± 12.1 | 0.764 |
| Body mass index (kg/m2) | 24.6 ± 3.3 | 24.6 ± 3.2 | 24.7 ± 3.4 | 0.821 |
| Hypertension | 155 (62.0%) | 80 (64.0%) | 75 (60.0%) | 0.596 |
| Diabetes mellitus | 73 (29.2%) | 37 (29.6%) | 36 (28.8%) | 1.000 |
| Hyperlipidemia | 82 (32.8%) | 44 (35.2%) | 38 (30.4%) | 0.488 |
| Smoking, current | 94 (37.6%) | 51 (40.8%) | 43 (34.4%) | 0.366 |
| Previous myocardial infarction | 41 (16.4%) | 20 (16.0%) | 21 (16.8%) | 1.000 |
| Previous CABG | 8 (3.2%) | 5 (4.0%) | 3 (2.4%) | 0.687 |
| Hemoglobin (g/dL) | 14.0 ± 2.2 | 14.1 ± 1.9 | 14.0 ± 2.4 | 0.778 |
| eGFR (mL/min/m2) | 69.8 ± 31.7 | 70.0 ± 33.4 | 70.0 ± 30.1 | 0.913 |
| Total cholesterol (mg/dL) | 192.1 ± 45.8 | 193.0 ± 42.2 | 191.2 ± 49.3 | 0.766 |
| Triglyceride (mg/dL) | 124.5 ± 87.4 | 126.3 ± 87.4 | 122.7 ± 87.6 | 0.749 |
| HDL-cholesterol (mg/dL) | 44.6 ± 10.9 | 44.6 ± 11.7 | 44.6 ± 10.1 | 0.968 |
| LDL-cholesterol (mg/dL) | 101.3 ± 35.0 | 101.1 ± 34.1 | 101.5 ± 36.1 | 0.928 |
| Baseline NT-proBNP (pg/mL) | 2,072.4 ± 5,975.7 | 2,024.4 ± 5,937.7 | 2,120.4 ± 6,037.1 | 0.895 |
| Baseline hsCRP (mg/dL) | 1.0 ± 2.2 | 0.9 ± 1.9 | 1.1 ± 2.4 | 0.508 |
| CK-MB elevation* | 101 (40.4%) | 50 (40.0%) | 51 (40.8%) | 1.000 |
| Troponin-I elevation* | 174 (69.6%) | 84 (67.2%) | 90 (72.0%) | 0.440 |
| Ischemic ECG change | 0.113 | |||
| ST depression | 74 (29.6%) | 36 (28.8%) | 38 (30.4%) | |
| T-wave inversion | 60 (24.0%) | 32 (25.6%) | 28 (22.4%) | |
| Echocardiographic LV EF (%) | 56.1 ± 10.7 | 55.9 ± 11.0 | 56.2 ± 10.4 | 0.801 |
| TIMI risk score | 1.000 | |||
| Low (0-2) | 93 (37.2%) | 47 (37.6%) | 46 (36.8%) | |
| Intermediate (3-4) | 122 (48.8%) | 60 (48.0%) | 62 (49.6%) | |
| High (5-7) | 35 (14.0%) | 18 (14.4%) | 17 (13.6%) | |
| Culprit artery | 0.783 | |||
| Left main coronary artery | 5 (2.0%) | 2 (1.6%) | 3 (2.4%) | |
| Left anterior descending artery | 135 (54.0%) | 66 (52.8%) | 69 (55.2%) | |
| Left circumflex artery | 58 (23.2%) | 28 (22.4%) | 30 (24.0%) | |
| Right coronary artery | 51 (20.4%) | 29 (23.2%) | 22 (17.6%) | |
| CAD extent | 0.807 | |||
| 1 vessel disease | 88 (35.2%) | 44 (35.2%) | 44 (35.2%) | |
| 2 vessel disease | 73 (29.2%) | 35 (28.0%) | 38 (30.4%) | |
| 3 vessel disease | 89 (35.6%) | 46 (36.8%) | 43 (34.4%) | |
| Symptom-to-admission time (hr, median) | 58.8 ± 132.0 (7.0) | 50.9 ± 125.7 (5.2) | 66.7 ± 138.0 (12.0) | 0.151 |
| Admission to-PCI time (hr, median) | 43.3 ± 42.3 (29.5) | 43.6 ± 33.5 (39.2) | 43.1 ± 49.6 (24.0) | 0.915 |
| Concomitant medication | ||||
| Heparin | 239 (95.6%) | 123 (98.4%) | 116 (92.8%) | 0.065 |
| GpIIb/IIIa R antagonists | 54 (21.6%) | 29 (23.2%) | 25 (20.0%) | 0.651 |
| Tirofiban | 9 (3.6%) | 2 (1.6%) | 7 (5.6%) | 0.180 |
| Abciximab | 46 (18.4%) | 27 (21.6%) | 19 (15.2%) | 0.256 |
| Aspirin | 250 (100.0%) | 125 (100.0%) | 125 (100.0%) | 1.000 |
| Clopidogrel | 250 (100.0%) | 125 (100.0%) | 125 (100.0%) | 1.000 |
| Beta-blocker | 17 (69.6%) | 83 (66.4%) | 91 (72.8%) | 0.341 |
| ACEI | 153 (61.2%) | 79 (63.2%) | 74 (59.2%) | 0.603 |
| ARB | 40 (16.0%) | 19 (15.2%) | 21 (16.8%) | 0.864 |
| DHP CCB | 39 (15.6%) | 21 (16.8%) | 18 (14.4%) | 0.728 |
| Non-DHP CCB | 19 (7.6%) | 9 (7.2%) | 10 (8.0%) | 1.000 |
| Nitrates | 45 (18.0%) | 20 (16.0%) | 25 (20.0%) | 0.486 |
| Statin | 217 (86.8%) | 107 (85.6%) | 110 (88.0%) | 0.728 |
*>1×upper reference limit; CABG, coronary artery bypass grafting; eGFR, estimated glomerular filtration rate; HDL, high-density lipoprotein; LDL, low-density lipoprotein; NT-proBNP, N-terminal-proB-type natriuretic peptide; hsCRP, high-sensitivity C-reactive protein; CK-MB, creatine kinase-myocardial band; ECG, electrocardiography; LV EF, left ventricular ejection fraction; TIMI, thrombolysis in myocardial infarction; CAD, coronary artery disease; PCI, percutaneous coronary intervention; GpIIb/IIIa R, glycoprotein IIb/IIIa receptor; ACEI, angiotensin-converting-enzyme inhibitor; ARB, angiotensin receptor blocker; DHP CCB, dihydropyridine-calcium channel blocker.
Thirty-day clinical outcomes in propensity-score matched population
| Outcomes | All (n = 250) | Weekend group (n = 125) | Weekday group (n = 125) | |
|---|---|---|---|---|
| MACE | 22 (8.8%) | 16 (12.8%) | 6 (4.8%) | 0.041 |
| Cardiac death | 1 (0.4%) | 1 (0.8%) | 0 (0.0%) | 1.000 |
| Recurrent MI | 2 (0.8%) | 2 (1.6%) | 0 (0.0%) | 0.500 |
| Repeat revascularization | 2 (0.8%) | 2 (1.6%) | 0 (0.0%) | 0.500 |
| Urgent PCI | 20 (8.0%) | 14 (11.2%) | 6 (4.8%) | 0.064 |
| CK-MB elevation, overall | 157 (63.6%) | 85 (68.0%) | 72 (59.0%) | 0.120 |
| Peak CK-MB level | 52.0±92.4 | 62.6±95.1 | 41.5±88.8 | 0.072 |
| Troponin-I elevation, overall | 213 (86.2%) | 109 (87.2%) | 104 (52.2%) | 0.690 |
| Peak Troponin-I level | 17.3±34.5 | 23.0±43.7 | 11.6±20.5 | 0.009 |
MACE, major adverse cardiac event; MI, myocardial infarction; PCI, percutaneous coronary intervention; CK-MB, creatine kinase-myocardial band.
Fig. 4Thirty-day MACE-free survival. (A) MACE-free survival in all patients. The cumulative 30-day MACE-free survival rate is significantly lower in patients admitted during the weekend (dotted line) compared to patients admitted during the weekday (solid line). Survival curves begin to diverge at day 1 and continue to separate throughout the 30-day follow-up period. (B) MACE-free survival in propensity-matched population. The cumulative 30-day MACE-free survival rate is significantly lower in the weekend group in the propensity score-matched population, too. MACE, major adverse cardiac events.
Adjusted risk of 30-day MACE in sequential Cox models
| Variable in Cox model | Hazard ratio (95% confidence interval)* | |||
|---|---|---|---|---|
| Weekend admission only | Weekend + clinical characteristics | Weekend + clinical + time factors | Weekend + clinical + time + severity factors | |
| Weekend admission | 2.13 (1.26-3.60) | 2.20 (1.29-3.73) | 3.01 (1.73-5.23) | 2.84 (1.61-5.00) |
| Age | 1.00 (0.98-1.03) | 1.01 (0.98-1.03) | 1.00 (0.98-1.03) | |
| Male sex | 1.46 (0.74-2.87) | 1.25 (0.63-2.45) | 1.14 (0.57-2.58) | |
| Hypertension | 0.68 (0.37-1.22) | 0.81 (0.44-1.46) | 0.85 (0.47-1.55) | |
| Diabetes mellitus | 0.89 (0.49-1.63) | 0.88 (0.48-1.61) | 0.89 (0.48-1.65) | |
| Hyperlipidemia | 0.79 (0.42-1.48) | 0.79 (0.42-1.49) | 0.80 (0.42-1.50) | |
| Smoking, current | 0.76 (0.40-1.45) | 0.78 (0.41-1.52) | 0.73 (0.38-1.42) | |
| Previous myocardial infarction | 1.67 (0.87-3.21) | 1.44 (0.75-2.79) | 1.66 (0.78-3.52) | |
| Previous CABG | 1.20 (0.28-5.06) | 1.33 (0.32-5.55) | 1.57 (0.35-6.93) | |
| Symptom-to-admission time | 1.00 (1.00-1.00) | 1.00 (1.00-1.00) | ||
| Admission-to-PCI time | 0.97 (0.95-0.98) | 0.97 (0.95-0.98) | ||
| Baseline Troponin-I elevation | 1.79 (0.94-3.41) | |||
| Ischemic ECG change | 0.68 (0.38-1.20) | |||
| TIMI scores | 1.01 (0.76-1.34) | |||
*The hazard ratios are derived from sequential Cox proportional-hazard models that included variables that may affect 30-day MACE.
Analysis of subgroup of patients with urgent PCI
| Parameters | All (n = 49) | Weekend group (n = 21) | Weekday group (n = 28) | |
|---|---|---|---|---|
| Reason for urgent PCI | 0.215 | |||
| Refractory angina | 28 (57.1%) | 15 (71.4%) | 13 (46.4%) | |
| Hemodynamic instability | 10 (20.4%) | 3 (14.3%) | 7 (25.0%) | |
| Electrical instability | 11 (22.4%) | 3 (14.3%) | 8 (28.6%) | |
| Time interval from reason to urgent PCI (min, median) | 118.8 ± 46.7 (109.0) | 107.4 ± 42.2 (95.0) | 127.4 ± 48.8 (119.0) | 0.139 |
| Age | 62.1 ± 12.5 | 59.9 ± 13.5 | 63.8 ± 11.7 | 0.287 |
| Sex (male) | 38 (77.6%) | 18 (85.7%) | 20 (71.4%) | 0.311 |
| Height (cm) | 163.9 ± 9.0 | 165.0 ± 8.3 | 163.1 ± 9.6 | 0.472 |
| Body weight (kg) | 64.6 ± 12.2 | 64.8 ± 12.1 | 64.4 ± 12.4 | 0.926 |
| Body mass index (kg/m2) | 23.9 ± 3.3 | 23.6 ± 3.1 | 24.0 ± 1.8 | 0.641 |
| Hypertension | 26 (53.1%) | 8 (38.1%) | 18 (64.3%) | 0.069 |
| Diabetes mellitus | 11 (22.4%) | 5 (23.8%) | 6 (21.4%) | 0.843 |
| Hyperlipidemia | 12 (24.5%) | 5 (23.8%) | 7 (25.0%) | 0.924 |
| Smoking, current | 16 (32.7%) | 7 (33.3%) | 9 (32.1%) | 0.930 |
| Previous myocardial infarction | 12 (24.5%) | 6 (28.6%) | 6 (21.4%) | 0.565 |
| Previous CABG | 2 (4.1%) | 1 (4.8%) | 1 (3.6%) | 1.000 |
| Hemoglobin, g/dL | 13.9 ± 2.0 | 13.6 ± 2.3 | 14.0 ± 1.8 | 0.509 |
| eGFR (mL/min/m2) | 63.0 ± 30.2 | 70.3 ± 36.1 | 57.7 ± 24.1 | 0.148 |
| Total cholesterol (mg/dL) | 200.5 ± 43.4 | 191.3 ± 41.6 | 207.3 ± 44.2 | 0.206 |
| Triglyceride (mg/dL) | 121.2 ± 84.5 | 143.4 ± 114.3 | 105.6 ± 52.0 | 0.137 |
| HDL-cholesterol (mg/dL) | 42.4 ± 7.2 | 41.4 ± 5.8 | 43.0 ± 8.1 | 0.485 |
| LDL-cholesterol (mg/dL) | 101.1 ± 36.7 | 100.4 ± 37.8 | 101.6 ± 36.8 | 0.918 |
| NT-proBNP (pg/mL) | 2,489.4 ± 6,157.8 | 1,560.2 ± 3,617.1 | 3,168.5 ± 7,495.4 | 0.393 |
| hsCRP (mg/dL) | 1.3 ± 3.4 | 2.4 ± 5.1 | 0.6 ± 0.6 | 0.128 |
| CK-MB elevation* | 26 (53.1%) | 9 (42.9%) | 17 (60.7%) | 0.215 |
| Troponin-I elevation* | 36 (73.5%) | 16 (76.2%) | 20 (71.4%) | 0.709 |
| Ischemic ECG change | 0.480 | |||
| ST depression | 19 (38.8%) | 10 (47.6%) | 9 (32.1%) | |
| T-wave inversion | 4 (8.2%) | 1 (4.8%) | 3 (10.7%) | |
| Echocardiographic LV EF (%) | 54.6 ± 10.3 | 55.9 ± 9.2 | 53.6 ± 11.3 | 0.502 |
| TIMI risk score | 0.409 | |||
| Low (0-2) | 17 (34.7%) | 6 (28.6%) | 11 (39.3%) | |
| Intermediate (3-4) | 26 (53.1%) | 11 (52.4%) | 15 (53.6%) | |
| High (5-7) | 6 (12.2%) | 4 (19.0%) | 2 (7.1%) | |
| Culprit artery | 0.310 | |||
| Left main coronary artery | 2 (4.1%) | 1 (4.8%) | 1 (3.6%) | |
| Left anterior descending artery | 23 (46.9%) | 10 (47.6%) | 13 (46.4%) | |
| Left circumflex artery | 13 (26.5%) | 8 (38.1%) | 5 (17.9%) | |
| Right coronary artery | 10 (20.4%) | 2 (9.5%) | 8 (28.6%) | |
| CAD extent | 0.607 | |||
| 1 vessel disease | 22 (44.9%) | 8 (38.1%) | 14 (50.0%) | |
| 2 vessel disease | 11 (22.4%) | 6 (28.6%) | 5 (17.9%) | |
| 3 vessel disease | 16 (32.7%) | 7 (33.3%) | 9 (32.1%) | |
| Symptom-to-admission time (hr, median) | 37.3 ± 116.2 (5.5) | 32.2 ± 103.3 (5.2) | 41.1 ± 126.8 (6.0) | 0.793 |
| Admission-to-PCI time (hr, median) | 7.6 ± 7.6 (4.8) | 7.2 ± 8.6 (4.4) | 7.9 ± 7.0 (6.6) | 0.742 |
| Concomitant medications | ||||
| Heparin | 43 (87.8%) | 19 (90.5%) | 24 (85.7%) | 0.688 |
| GpIIb/IIIa R antagonists | 17 (34.7%) | 8 (38.1%) | 9 (32.1%) | 0.665 |
| Tirofiban | 2 (4.1%) | 0 (0.0%) | 2 (7.1%) | 0.500 |
| Abciximab | 15 (30.6%) | 8 (38.1%) | 7 (25.0%) | 0.325 |
| Aspirin | 49 (100%) | 21 (100%) | 28 (100%) | 1.000 |
| Clopidogrel | 49 (100%) | 21 (100%) | 28 (100%) | 1.000 |
| Beta-blocker | 32 (65.3%) | 17 (81.0%) | 15 (53.6%) | 0.070 |
| ACEI/ARB | 33 (67.3%) | 17 (81.0%) | 16 (57.1%) | 0.079 |
| Statin | 37 (75.5%) | 15 (71.4%) | 22 (78.6%) | 0.565 |
*>1×upper reference limit; PCI, percutaneous coronary intervention; CABG, coronary artery bypass grafting; eGFR, estimated glomerular filtration rate; HDL, high-density lipoprotein; LDL, low-density lipoprotein; NT-proBNP, N-terminal-proB-type natriuretic peptide; hsCRP, high-sensitivity C-reactive protein; CK-MB, creatine kinase-myocardial band; ECG, electrocardiography; LV EF, left ventricle ejection fraction; TIMI, thrombolysis in myocardial infarction; CAD, coronary artery disease; GpIIb/IIIa R, glycoprotein IIb/IIIa receptor; ACEI, angiotensin-converting-enzyme inhibitor; ARB, angiotensin receptor blocker.